Progyny (PGNY) COO Melissa B Cummings Sells $53K of Stock

Progyny, Inc. Chief Operating Officer Melissa B Cummings sold 1,879 shares of the healthcare benefits provider on October 14, 2026. The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Inside Melissa B Cummings's PGNY Trade

Cummings executed the sale at a price of $28.00 per share, yielding a total value of $52,612. The planned sale, executed under a pre-arranged Rule 10b5-1 trading plan, reduced her direct holdings by 2.75%. Following the transaction, Cummings retains 66,496 shares in the company. On the day of the trade, Progyny stock closed at $27.84.

Other Institutional Activity in Progyny

Institutional investors adjusted their holdings across recent reporting periods. Ameriprise Financial, Inc. reduced its holdings by 61,876 shares, ending with 2,763,514 shares worth about $74,227,987. Citadel Advisors Llc grew its holdings by 892,858 shares, a 100% increase to 1,879,717 shares valued at $47,964,359. Fort Washington Investment Advisors, Inc. reduced its holdings by 911,700 shares, ending with 1,636,371 shares worth approximately $43,952,926.

Progyny, Inc. Stock Down 1.0%

Shares recently traded around $27.17 as of October 17, 2026. The stock sits below its 52-week high of $33.06 and above its 52-week low of $16.10. Progyny shares trade above both their 50-day moving average of $26.45 and their 200-day moving average of $24.27.

Recent Earnings

Progyny reported trailing twelve month revenue of $1,310,764,032 and earnings of $0.92 per share. The company posts a net profit margin of 6.0% alongside a return on equity of 16.2%. The company's next earnings report is scheduled for November 5, 2026.

Dividend

Progyny does not pay a dividend to shareholders, registering a dividend payout ratio and dividend yield of 0.0% as the firm reinvests earnings into its fertility benefits operations.

Insider Buying and Selling at Progyny, Inc.

Insider transactions over recent months include several sales. Chief Financial Officer Mark S Livingston sold 2,517 shares on June 4, 2026, at $25.50 for $64,184. Later, Melissa B Cummings sold 2,244 shares on July 14, 2026, at $31.60 for $70,910. Director Kevin K Gordon sold 11,500 shares on September 10, 2026, at $27.94 for $321,358. General Counsel Allison Swartz sold 3,903 shares on September 23, 2026, at $26.10 for $101,868.

Analysts Set New Price Targets

Wall Street firms maintain active coverage on Progyny. Truist Securities maintained a Buy rating with a $36.0 target on August 13, 2026. Wells Fargo initiated an Overweight rating with a $37.0 target on August 20, 2026. JP Morgan maintained a Neutral rating with a $30.0 target on August 21, 2026. Citizens maintained a Market Outperform rating with a $33.0 target on September 8, 2026. Wells Fargo initiated another Overweight rating with a $37.0 target on September 30, 2026. Overall, the stock holds a consensus strong buy recommendation with a mean price target of $34.42.

About Progyny

Progyny operates as a benefits management company based in New York, offering specialized fertility, family building, and women's health benefits solutions across the United States. The firm provides differentiated plan designs that bundle smart cycle treatments with concierge-style support and a selective network of specialists.

Bottom Line

Investors will watch toward Progyny's upcoming earnings report on November 5, 2026, for further updates on the company's financial health. Form 4 filings will continue to track executive and director transactions.